A phase II study of Erlotinib plus Pemetrexed for Non Small Cell Lung Cancer with T790M negative previously treated with EGFR-TKI
Phase 2
Recruiting
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000008033
- Lead Sponsor
- Toho University Omori Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1) Presence of active interstitial pneumonia, radiation pneumonia, pneumoconiosis, or drug induced pneumonia 2) Uncontrolled pleural effusion, ascites, or pericardial effusion 3) Previously treated with Pemetrexed 4) Patients with active severe infections 5) Impossible cases with oral administration 6) Patients with uncontrollable complications 7) Pregnancy, breast feeding and suspected pregnancy 8) Active concomitant malignancy 9) Inappropriate patients for this study judged by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease control rate
- Secondary Outcome Measures
Name Time Method Response rate Overall survival Progression free survival Safety